0.5709
2.91%
-0.0171
Bioxcel Therapeutics Inc stock is traded at $0.5709, with a volume of 22,099.
It is down -2.91% in the last 24 hours and up +3.95% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$0.588
Open:
$0.571
24h Volume:
22,099
Relative Volume:
0.05
Market Cap:
$23.58M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.0803
EPS:
-7.11
Net Cash Flow:
$-155.03M
1W Performance:
+9.70%
1M Performance:
+3.95%
6M Performance:
-71.60%
1Y Performance:
-85.36%
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
BTAI | 0.5709 | 23.58M | 1.38M | -179.05M | -155.03M | -7.11 |
VRTX | 448.31 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.42 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.40 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.98 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.31 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
Jul-07-22 | Initiated | Mizuho | Buy |
Apr-06-22 | Reiterated | BofA Securities | Buy |
Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
Apr-09-21 | Initiated | Berenberg | Buy |
Feb-01-21 | Initiated | UBS | Buy |
Oct-30-20 | Initiated | Goldman | Buy |
Sep-02-20 | Initiated | Jefferies | Buy |
Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
Jun-04-20 | Initiated | Guggenheim | Buy |
Apr-01-20 | Initiated | BofA/Merrill | Buy |
Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance
BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartzy
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com
BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada
BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World
BioXcel advances trials for acute agitation treatments - Investing.com India
BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire
BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com
BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN
BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia
BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India
BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan
BioXcel Therapeutics reports executive transition - Investing.com India
BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia
Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily
BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia
BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com South Africa
BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa
Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com
BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com
BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com
BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):